Let Them Eat Prozac

Let Them Eat Prozac chronicles the development and marketing of SSRI antidepressants, with a focus on Prozac and its manufacturer Eli Lilly. David Healy, a psychiatrist and historian, presents documentation and first-hand accounts of clinical trials, regulatory decisions, and pharmaceutical industry practices from the 1970s through early 2000s. The book tracks key figures in psychiatry and pharmaceutical development while examining the scientific evidence behind SSRIs. Healy documents his own involvement in investigating potential links between these medications and adverse effects, including his role as an expert witness in related court cases. Through medical records, corporate documents, and regulatory filings, the text reconstructs the sequence of events that transformed how depression is diagnosed and treated. The narrative follows both the broad institutional changes in mental health care and specific cases that shaped public understanding of antidepressants. This work raises fundamental questions about pharmaceutical regulation, corporate influence in medicine, and the changing relationship between doctors and patients. The investigation serves as a case study in how commercial interests can impact scientific research and public health policy.

Readers describe this as a detailed exposé of the pharmaceutical industry's influence on antidepressant research and marketing. Many cite Healy's insider perspective as a psychiatrist and expert witness in SSRI-related court cases. Readers appreciated: - Clear documentation of pharmaceutical company practices - Personal case studies and clinical trial data - Historical context of drug development - Discussion of suppressed research findings Common criticisms: - Dense academic writing style - Technical medical terminology - Repetitive in later chapters - Some found it one-sided against pharmaceuticals Ratings across platforms: Goodreads: 4.1/5 (157 ratings) Amazon: 4.4/5 (48 reviews) Several reviewers noted the book changed their view of antidepressants. One reader wrote: "Eye-opening look at how drug companies manipulate data." Another stated: "Important but tough reading - took me weeks to get through the medical jargon."

Bad Pharma by Ben Goldacre Documents how pharmaceutical companies manipulate clinical trials, withhold data, and influence medical research to market their drugs.

Anatomy of an Epidemic by Robert Whitaker Investigates the rise of psychiatric medications in America and their long-term effects on patients' mental health outcomes.

Mad in America by Robert Whitaker Chronicles the history of schizophrenia treatment in America and examines the pharmaceutical industry's influence on mental health care.

Pharmageddon by David Healy Examines how pharmaceutical marketing has transformed healthcare systems and changed the way society views illness and treatment.

The Emperor's New Drugs by Irving Kirsch Presents research data challenging the effectiveness of antidepressants and explores the placebo effect in depression treatment.

🔹 David Healy testified as an expert witness in several high-profile court cases involving antidepressants and suicide, including cases against pharmaceutical companies that helped shape drug industry regulations. 🔹 The book reveals that an early clinical trial of Prozac in Germany was halted due to concerns about suicidal thoughts in test subjects, but this information wasn't widely shared when the drug launched in other countries. 🔹 The author established a unique research database called RxISK.org, where patients can report drug side effects directly and access information about medication risks not commonly disclosed in standard documentation. 🔹 Prozac was initially developed as a potential treatment for high blood pressure before researchers discovered its antidepressant properties, leading to its eventual approval for depression in 1987. 🔹 The book's publication in 2004 contributed to the FDA's decision to implement "black box" warning labels on antidepressants, alerting patients about increased suicide risks, particularly in young people.